Overview

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Status:
Completed

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease. The study will be 16 weeks in duration; 2-week run-in period, 12-week double-blind treatment, and 2-week follow-up phone visit.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca
Forest Laboratories

Collaborator:

Almirall, S.A.

Treatments:

Bromides